Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586123 | 0.79 | CD274 (0.40) | CD274CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL14653527 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11SIGMAR1ATR | |
| SCHEMBL18483949 | 0.77 | CD274 (0.43) | CD274CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL22816839 | 0.77 | CD274 (0.40) | CD274CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL22381074 | 0.77 | CD274 (0.39) | CD274CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL31413798 | 0.76 | ALDH1A1 (0.33) | CYP4F2CYP4A11KMT2A | |
| SCHEMBL25232393 | 0.76 | CD274 (0.40) | CD274CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL18485036 | 0.76 | CD274 (0.40) | CD274CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL18485074 | 0.76 | KDM5B (0.38) | CYP4F2CYP4A11ATR | |
| SCHEMBL31392637 | 0.75 | CYP4F2 (0.44) | CYP4F2CYP4A11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| EP-4185293-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | The Regents of The University of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022020424-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | CD274 4349/4885CYP4F2 4078/4885CYP4A11 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.